All News
Methotrexate significantly lowers Systolic BP
Australian researchers have shown that methotrexate (MTX) has another secondary, beneficial effect by significantly lowering systolic blood pressure, and contributes to its well docuented cardioprotive effecs.
Read Article
Multi-omics, biomarkers, rheumatoid arthritis and pulmonary fibrosis
Rheumatoid arthritis (RA) is a common autoimmune disease, and approximately 30%-40% of patients develop pulmonary complications such as idiopathic pulmonary fibrosis (IPF), but the causal relationship between the two has long been unclear.
Read Article
ACR Concerns on the Scientific Integrity at the CDC
d
ACR
On behalf of the American College of Rheumatology (ACR), we express deep concern over recent developments at the Centers for Disease Control and Prevention (CDC) that appear to undermine the agency’s longstanding commitment to science-based public health policy.
Read Article
Crepitus Does Not Predict Earlier/Worse OA
d
EurekAlert!
Young adults who experience grinding or clicking sounds in their knees post-surgery may be alarmed, but new research from La Trobe University suggests these sounds may not signal early-onset osteoarthritis.
Read Article
Retrospective Korean study of #RA & ILD pts (n 151) - ILD duration & UIP pattern significantly affected prognosis. 62% were non-smokers, DAS28=4.9, UIP in 60%. @4 years, ILD progressed in 58%; mortality=21%. MTX did not affect progression or mortality. https://t.co/1XNcWsAuea https://t.co/hsUWi27OtQ
Dr. John Cush RheumNow ( View Tweet)
Global prevalence of Hidradenitis suppurativa (HS) is 0.99%, but varies globally between 0.67% and 1.46%. HS is assoc w/ female sex. Based on a meta-analysis 22 743 participants, identifying 247 HS pts. https://t.co/TtKdfKiIn3 https://t.co/zOIVUlF5E8
Dr. John Cush RheumNow ( View Tweet)
High unemployment in Dutch SLE patients, linked to SLE Sxs & Dz duration.
Supervisor support helps with employment. https://t.co/E5jqmUHqo7
Dr. John Cush RheumNow ( View Tweet)
Biomarkers in ILD
Join Elena K. Joerns, MD, as she highlights key insights on the role of biomarkers in ILD. Sponsored By: Boehringer Ingelheim. https://t.co/Mxg9P50m7C #ILD #Rheumatology https://t.co/tQUvwHD5cX
Dr. John Cush RheumNow ( View Tweet)
September is Pulmonary Fibrosis Awareness month. PF & ILD affect more than 250,000 Americans. The Pulmonary Fibrosis Foundation (PFF), will lead a nationwide campaign to raise awareness https://t.co/BYKeLcFP2U https://t.co/746CyLCT0z
Links:
Dr. John Cush RheumNow ( View Tweet)
Elevated serum levels of interleukin-18 discriminate Still's disease from other autoinflammatory conditions. Sera from 53 mSAID, 220 guSAID, 49 controls show IL-18 signif increased in Still's Dz; free IL-18 levels were selectively higher in Still's disease. https://t.co/oAd3JwDR5D
Dr. John Cush RheumNow ( View Tweet)
J&J announced it has halted its combination biologic study in difficult to treat RA. Phase 2a DAISY proof-of-concept studied the combo of nipocalimab and TNFi in refractory RA, but 12 wk results failed to evidence of efficacy. https://t.co/T4n4GNqtVC v https://t.co/eSAwrEIYHc
Dr. John Cush RheumNow ( View Tweet)
GLP-1 receptor agonists use assoc w/ lower risk of uveitis compared vs controls. EHR study 258 026 ea on GLP-1RA or not. GLP-1RAs exhibited roughly half the risk of developing uveitis. Protective effect greater than that of metformin & insulin but lower than SGLT2i https://t.co/w311b6swc3
Dr. John Cush RheumNow ( View Tweet)
ACR Urges Alaska and Montana to Strengthen Rheumatology Care
The American College of Rheumatology (ACR) is calling on Alaska and Montana to seize the opportunity to address critical gaps in rheumatology care by accessing funding from the Rural Health Transformation Program https://t.co/exHRCORcCG
Dr. John Cush RheumNow ( View Tweet)
Review of cancer-associated myositis (CAM) & assoc myositis-specific or myositis-associated autoantibodies. 2017 meta-analysis 5 studies & 4538 pts w/ DM or PM, the cancer risk (SIR) for DM = 4.66, but PM = 1.75. Cancer risk ^^ w/ Low serum KL-6, TIF1γ, NXP2, HMGCR Abs https://t.co/xsOt4wPIXB
Dr. John Cush RheumNow ( View Tweet)
High cancer risk in myositis patients linked to autoantibodies- TIFF1g, NXP2, HMGCR. https://t.co/CECO78ESHi
Dr. John Cush RheumNow ( View Tweet)
Interstitial lung disease is a group of conditions that cause inflammation and scarring in the lungs.
This JAMA Patient Page describes types and causes of interstitial lung disease as well as its diagnosis, treatment, and prognosis.
https://t.co/WELKKR0SX7 https://t.co/ykzR16ja3L
Links:
JAMA JAMA_current ( View Tweet)
Anti-MDA5 DM is assoc w/ rapidly progr ILD & mortality risk. 26 MD5+ DM pts (age 56.6 yrs; 7/26 male) Sxs: Gottrón’s (81%), ILD (73%), periungual erythema (69%), heliotrope (61%), V-sign (42%), arthritis (42%), weakness (38%), mechanic’s (35%), Raynaud’s (19%). 7/19 RP-ILD died https://t.co/ugbmKlXsBp
Dr. John Cush RheumNow ( View Tweet)
JAMA: Cognitive functional therapy (CFT) is effective in control of chronic low back pain. Study of 500 LBP pts Rx w/ usual care, CFT, or CFT with biofeedback over 3 mos. F/U of ~ 300 pts found that the benefits extended up to 3 years after the intervention. https://t.co/dLv53M7Xkp
Dr. John Cush RheumNow ( View Tweet)
LIVE September 9th, 7PM EST
Join Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator, as they review ACR & EULAR #ILD guidelines.
Where are we now? Where are we going?
Don’t miss it!
https://t.co/PVo0dbQLCn
#Rheumatology #ILD https://t.co/gp1qfeEt3S
Dr. John Cush RheumNow ( View Tweet)
Long-term Lab Monitoring in RA is Inefficient
Annals of Internal Medicine has published a retrospective study of long-term routine laboratory toxicity monitoring (lt-RLTM) in patients receiving disease-modifying antirheumatic drug (DMARD) therapy showing that most very abnormal https://t.co/hytyH1qqED
Dr. John Cush RheumNow ( View Tweet)
